Evidence map›Paper›PMID 38356658›Full record

ArticleComputational and structural biotechnology journal2024

Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation.

Feifei Wei, Taku Kouro, Yuko Nakamura, Hiroki Ueda, Susumu Iiizumi, Kyoko Hasegawa, Yuki Asahina, Takeshi Kishida, Soichiro Morinaga, Hidetomo Himuro and 6 more

Open access · goldAbstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Feifei WeiDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Taku KouroDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Yuko NakamuraIsotope Science Center, The University of Tokyo, Tokyo, Japan.
Hiroki UedaResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Susumu IiizumiDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Kyoko HasegawaDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Yuki AsahinaDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Takeshi KishidaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Soichiro MorinagaDepartment of Hepato-Biliary and Pancreatic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Hidetomo HimuroDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Shun HoraguchiDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Kayoko TsujiDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Yasunobu ManoDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Norihiro NakamuraResearch & Early Development Division, BrightPath Biotherapeutics Co., Ltd., Kawasaki, Japan.
Takeshi KawamuraIsotope Science Center, The University of Tokyo, Tokyo, Japan.
Tetsuro SasadaDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Kanagawa Prefectural Hospital Organization · JPThe University of Tokyo · JPBrightPath Biotherapeutics (Japan) · JPNihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurately identifying neoantigens is crucial for developing effective cancer vaccines and improving tumor immunotherapy. Mass spectrometry-based immunopeptidomics has emerged as a promising approach to identifying human leukocyte antigen (HLA) peptides presented on the surface of cancer cells, but false-positive identifications remain a significant challenge. In this study, liquid chromatography-tandem mass spectrometry-based proteomics and next-generation sequencing were utilized to identify HLA-presenting neoantigenic peptides resulting from non-synonymous single nucleotide variations in tumor tissues from 18 patients with renal cell carcinoma or pancreatic cancer. Machine learning was utilized to evaluate Mascot identifications through the prediction of MS/MS spectral consistency, and four descriptors for each candidate sequence: the max Mascot ion score, predicted HLA binding affinity, aliphatic index and retention time deviation, were selected as important features in filtering out identifications with inadequate fragmentation consistency. This suggests that incorporating rescoring filters based on peptide physicochemical characteristics could enhance the identification rate of MS-based immunopeptidomics compared to the traditional Mascot approach predominantly used for proteomics, indicating the potential for optimizing neoantigen identification pipelines as well as clinical applications.

Indexed as

Aliphatic indexImmunopeptidomicsMachine learningMass spectrometry

Identifiers

PMID38356658
PMCPMC10864759
OpenAlexW4391508033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.